Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNon-cash ItemsShare-based CompensationShares IssuedShares Repurchased
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Roivant Sciences (ROIV) Cash from Operations (2020 - 2025)

Historic Cash from Operations for Roivant Sciences (ROIV) over the last 6 years, with Q4 2025 value amounting to -$196.5 million.

  • Roivant Sciences' Cash from Operations rose 7053.71% to -$196.5 million in Q4 2025 from the same period last year, while for Dec 2025 it was -$1.3 billion, marking a year-over-year increase of 2971.49%. This contributed to the annual value of -$839.5 million for FY2025, which is 969.37% down from last year.
  • As of Q4 2025, Roivant Sciences' Cash from Operations stood at -$196.5 million, which was up 7053.71% from -$185.7 million recorded in Q3 2025.
  • In the past 5 years, Roivant Sciences' Cash from Operations registered a high of -$120.6 million during Q3 2021, and its lowest value of -$666.9 million during Q4 2024.
  • In the last 5 years, Roivant Sciences' Cash from Operations had a median value of -$204.4 million in 2025 and averaged -$314.3 million.
  • In the last 5 years, Roivant Sciences' Cash from Operations crashed by 18770.79% in 2021 and then skyrocketed by 7053.71% in 2025.
  • Roivant Sciences' Cash from Operations (Quarter) stood at -$530.3 million in 2021, then fell by 25.28% to -$664.3 million in 2022, then rose by 1.13% to -$656.8 million in 2023, then dropped by 1.53% to -$666.9 million in 2024, then surged by 70.54% to -$196.5 million in 2025.
  • Its Cash from Operations was -$196.5 million in Q4 2025, compared to -$185.7 million in Q3 2025 and -$204.4 million in Q2 2025.